Melissa Komlosi Melendez, MSN RN CPNP-PCClinical Trial Nurse Navigator

Melissa Komlosi Melendez is a board-certified Pediatric Nurse Practitioner through PNCB with APHON Chemotherapy/Biotherapy certification. She was an oncology nurse practitioner at Rainbow Babies and Children’s Hospital in Cleveland for 10 years. During that time, she worked with general oncology patients in the inpatient and outpatient settings, and was the nurse practitioner for the Anti-Coagulation Program and Thrombophilia Program and helped coordinate the Young Women with Bleeding/Clotting Disorders Clinic.

Melissa served in many leaderships roles throughout her career with involvement in numerous committees, development and implementation of the electronic medical record, and participation in professional organizations, including serving as the treasurer to her local APHON chapter from 2014–2018 and being a member of both APHON and COG Nursing Discipline throughout her career. Prior to her role as a nurse practitioner, she was an assistant nurse manager and a registered nurse on the inpatient pediatric oncology and bone marrow transplant unit. For over 10 years, she has been Clinical Faculty for MSN students at multiple universities and colleges, holding a position as Part-time Contributing Faculty at Walden University since 2016. Melissa graduated from Baldwin Wallace University with a Bachelor of Science in Biology and obtained her nursing degree and Master of Science in Nursing at Case Western Reserve University. Since 2019, she has been supporting the Leukemia & Lymphoma Society’s efforts to provide the most comprehensive information and support resources for blood cancer patients and their families in her role as a Clinical Trial Nurse Navigator in the Clinical Trial Support Center. Melissa is part of a team of nurses that helps patients and their caregivers with guidance, education, and support through the continuum of their treatment, as well as provides them with an individualized, patient-friendly list of appropriate clinical trials to discuss with the health care team.

No Easy Target! What’s new in AML Therapy? (225)
The Leukemia & Lymphoma Society
Rye Brook, New York